BioLight Life Sciences (TLV:BOLT) touted data today from a Phase I/IIa clinical trial evaluating its Eye-D latanoprost insert.
The device successfully lowered intraocular pressure during the study’s 12-week period and had a favorable safety profile, according to the Israel-based company.
Get the full story at our sister site, Drug Delivery Business News.
The post BioLight’s glaucoma insert succeeds in Phase I/IIa trial appeared first on MassDevice.
from MassDevice http://ift.tt/2v0HZcT
Cap comentari:
Publica un comentari a l'entrada